This grant, part of the NHLBI Catalyze Program, is for supporting the early-stage translation of basic science discoveries into viable diagnostic and therapeutic candidates. Its core purpose is to provide comprehensive support for prototype testing and design modification of medical devices, develop assays for diagnostic disease targets, and create research tools to address Heart, Lung, Blood, and Sleep (HLBS) diseases and disorders. The program aims to facilitate the transition of these innovations towards human testing by preparing potential products for subsequent in vivo testing, including optimization, safety, and efficacy studies. Additionally, it seeks to cultivate translational researchers skilled in product development and entrepreneurship, ultimately advancing projects to meet criteria for preclinical programs and further development.
Opportunity ID: 357340
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-HL-26-020 |
| Funding Opportunity Title: | Catalyze: Product Definition Medical Device Prototype Optimization (R33 – Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.233 — National Center on Sleep Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 22, 2024 |
| Last Updated Date: | Nov 22, 2024 |
| Original Closing Date for Applications: | Dec 23, 2027 |
| Current Closing Date for Applications: | Dec 23, 2027 |
| Archive Date: | Jan 28, 2028 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) Native American tribal governments (Federally recognized) For profit organizations other than small businesses County governments Private institutions of higher education State governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Small businesses City or township governments Native American tribal organizations (other than Federally recognized tribal governments) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-26-020.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357340 Full Announcement-RFA-HL-26-020 -> RFA-HL-26-020-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288957 | Jan 11, 2025 | Dec 23, 2027 | View |
Package 1
Mandatory forms
357340 RR_SF424_5_0-5.0.pdf
357340 PHS398_CoverPageSupplement_5_0-5.0.pdf
357340 RR_OtherProjectInfo_1_4-1.4.pdf
357340 PerformanceSite_4_0-4.0.pdf
357340 RR_KeyPersonExpanded_4_0-4.0.pdf
357340 RR_Budget_3_0-3.0.pdf
357340 PHS398_ResearchPlan_5_0-5.0.pdf
357340 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357340 RR_SubawardBudget30_3_0-3.0.pdf
357340 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
